Immunic Therapeutics
Immunic Therapeutics is a clinical-stage biopharmaceutical company focused on developing oral immunology therapies for chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company's lead candidate, IMU-838, is a selective immune modulator that inhibits the enzyme dihydroorotate dehydrogenase (DHODH), currently undergoing Phase 2 clinical trials for ulcerative colitis and relapsing-remitting multiple sclerosis, as well as a Phase 2 trial for Crohn's disease. Additionally, Immunic is advancing IMU-935, an inverse agonist targeting RORγt, and IMU-856, which aims to restore intestinal barrier function in patients suffering from various gastrointestinal conditions, including inflammatory bowel disease and irritable bowel syndrome with diarrhea. Headquartered in New York, Immunic Therapeutics aims to enhance treatment options for patients with these challenging diseases.
As of April 12, 2019, Vital Therapies, Inc. was acquired by Immunic AG, in a reverse merger transaction. Vital Therapies, Inc., a biotherapeutic company, focuses on developing cell-based therapies for the treatment of acute forms of liver failure. The company was formerly known as Vitagen Acquisition Corp. and changed its name to Vital Therapies, Inc. in June 2003. Vital Therapies, Inc. was founded in 2003 and is based in San Diego, California.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.